Chief Commercial Officer (CCO)
Andrew began his career in the pharmaceutical industry more than 15 years’ ago as an organic chemist. Following completion of his PhD at Newcastle University, Andrew joined Onyx Scientific as a development chemist before moving into a business development role. Andrew then joined Aesica Pharmaceuticals where he held various positions in business development, project management and corporate development.
Andrew joined Sterling (then Shasun) in 2015 and now has overarching responsibility for the commercial performance of the business, including the global business development, partnership management and marketing teams.